Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen, Inc. Reports on Additions to Its Industry-Leading ADC Technology Portfolio at AACR-NCI-EORTC Conference
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN) today reported on additions to the Company's portfolio of antibody-drug conjugate (ADC) technologies at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics meeting being held in Boston, MA.
View HTML
Toggle Summary ImmunoGen, Inc. Announces SAR566658 Clinical Findings Reported at AACR-NCI-EORTC Conference
First clinical data reported for this novel antibody-drug conjugate (ADC) for ovarian, breast, and other epithelial cancers. First of four partner compounds with clinical data presentations expected this quarter. WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc.
View HTML
Toggle Summary ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2014 Financial Results
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m.
View HTML
Toggle Summary ImmunoGen, Inc. Announces Presentations at Upcoming AACR-NCI-EORTC Anticancer Conference
First clinical data to be reported for SAR566658 , further expanding the extensive body of data reported with ImmunoGen's maytansinoid antibody-drug conjugate (ADC) technology. Presentations on new ADC technologies, including a new class of payload agents, highlight ImmunoGen's continuing
View HTML
Toggle Summary ImmunoGen, Inc. Announces New License Agreement
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that Novartis has licensed the exclusive right to use the Company's ADC technology to develop
View HTML
Toggle Summary ImmunoGen, Inc. Announces Results from Kadcyla® Phase III Trial, TH3RESA, Being Presented Today at the European Cancer Congress
Roche's Kadcyla found to significantly extend duration of progression-free survival in patients with advanced HER2-positive breast cancer in second large randomized trial. Kadcyla comprises Roche's trastuzumab antibody and ImmunoGen's ADC technology; it has been approved for marketing in several
View HTML